High MYC and/or BCL2 protein expression, as assessed by immunohistochemistry, has also been shown to have an adverse prognostic impact in systemic DLBCL, independent of MYC rearrangement and COO subtype [10]–[12]. Here, MYC is linked to diffuse large B-cell lymphoma.